Chargement en cours...
Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma
Targeting MAPK pathway in mutant BRAF melanoma with the specific BRAF inhibitor vemurafenib showed robust initial responses in the majority of patients followed by relapses due to acquired resistance to the drug. In (V600E)BRAF melanoma cell lines, senescence-associated β-galactosidase activity is o...
Enregistré dans:
| Publié dans: | Oncotarget |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Impact Journals LLC
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6112757/ https://ncbi.nlm.nih.gov/pubmed/30159130 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25879 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|